zepbound glp 1 FDA approval for (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Oksana Aron, M.D., Medical Weight

Description

1 Introduction Incretin peptides are secreted from the intestine after nutrient ingestion and enhance glucose-stimulated insulin secretion ( 2 Weight loss pharmacotherapies 2.1 GLP-1R and GIPR agonism reduce body weight in patients with obesity Early GLP-1R agonists were approved to treat T2D ( The mechanism underlying the impressive weight loss potential of GLP-1R agonists is primarily, if not exclusively, mediated by a reduction in energy intake

As the potential uses of these drugs expand, such as with recent approvals to prevent heart attacks and strokes in adults with cardiovascular disease who are overweight, the high cost and increased demand for these drugs may increase health spending

Stanciu GD, Luca A, Rusu RN, Bild V, Beschea Chiriac SI, Solcan C, et al

Current Opinion in Pediatrics , 36(5), 542-546

The most prevalent factors employers take into consideration for GLP-1 drug coverage for obesity care include: Obesity as a risk factor for chronic conditions and associated costs67% Drug shortages47% Impact/effectiveness of cost-control mechanisms47% Existing coverage through government programs40% Long-term costs33% Patient and prescriber demand33%